GSK Acquires US Biopharma Company for $2.2 Billion Dollars

GlaxoSmithKline (GSK) has announced its acquisition of a US biopharmaceutical company, RAPT Therapeutics, for a sum of 2.2 billion dollars. This strategic move marks GSK’s first bolt-on acquisition under the leadership of new chief executive Luke Miels.

The acquisition of RAPT Therapeutics, a California-based clinical-stage company, is expected to enhance GSK’s drug pipeline significantly. RAPT is focused on developing therapies aimed at addressing inflammatory and immunologic diseases.

Included in the deal is ozureprubart, a long-acting monoclonal antibody currently in mid-to-late stage development. This treatment offers protection against food allergens and is designed for less frequent dosing, occurring every twelve weeks. In contrast, existing treatments require injections every two to four weeks, which can pose a significant burden for many patients, particularly children.

The acquisition is projected to close in the first quarter of the year. GSK aims to bolster its product pipeline further and expects that ozureprubart will be a promising addition, contributing to the company’s overall growth strategy.

In related news, GSK has also reached an agreement with Shionogi, its Japanese partner, to acquire Pfizer’s 11.7 percent stake in ViiV Healthcare, their HIV joint venture. This restructuring will increase Shionogi’s stake in ViiV to 21.7 percent, while GSK will maintain its majority interest with 78.3 percent.

GSK’s share price closed at 17.95 pounds, reflecting a decrease of 1.1 percent on the London Stock Exchange. Despite this decline, investor confidence remains higher, driven by GSK’s ongoing commitment to research and development in the biopharmaceutical sector.

The executive team at GSK, under Miels’ leadership, is targeting 15 major product launches expected to fulfil a key sales growth ambition of over 40 billion pounds by 2031.